How Big Is the Lung Cancer Diagnostics Market | Segments & Forecast 2032

Q: What is the expected market size of the lung cancer diagnostics market?

The lung cancer diagnostics market is anticipated to exceed USD 5.22 billion by 2032 due to increasing focus on early-stage cancer detection technologies.

Q: Who are the key players in the lung cancer diagnostics market?

Prominent players include Roche Diagnostics, Thermo Fisher, Illumina, QIAGEN, Agilent, and Bio-Rad, known for their molecular diagnostic innovations.

Q: How is technology reshaping the lung cancer diagnostics market?

AI, genomic testing, and liquid biopsy are transforming the lung cancer diagnostics market by enabling earlier, faster, and more accurate diagnoses.

Q: What healthcare trends are impacting the lung cancer diagnostics market?

The emphasis on personalized care, early screening programs, and growing investments in cancer diagnostics are shaping the lung cancer diagnostics market.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6962

Publication Date: Jul 2025

How Big Is the Lung Cancer Diagnostics Market?

According to 6Wresearch internal database and industry insights, Global lung cancer diagnostics market was valued at USD 3.6 billion in 2025 and is forecast to surpass USD 5.22 billion by 2032, growing at a CAGR of 5.60%.

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global lung cancer diagnostics market.

View Main Report Schedule Analyst Call

The growing prevalence of lung cancer, rising awareness campaigns, and rapid adoption of low-dose CT scans and biomarker-based tests are all significantly contributing to growth in the market. There is also continuous innovation in molecular diagnostics and liquid biopsy is improving the rates of early detection.

Growth Factors of the Lung Cancer Diagnostics Market

Increasing incidence of lung cancer fuels diagnostic demand
Adoption of advanced imaging and molecular testing tools is rising
Public screening programs are expanding across urban regions
Growing acceptance of liquid biopsy for non-invasive diagnosis
Technological integration supports personalized oncology diagnostics
Rising healthcare investments in oncology-focused infrastructure

Lung Cancer Diagnostics Market Trends

The lung cancer diagnostics market is gaining significant traction through the use of genomic profiling and next-generation sequencing to identify mutations in cancer early. Hospitals and laboratories are continuing to adopt multiple AI-enabled platforms to help identify mutations early in the diagnostic workflow and alleviate false negatives. There is a strong push to identify lung cancer earlier so that targeted and more efficacious treatment regimens can be implemented.

Emerging Developments in the Lung Cancer Diagnostics Market

Significant innovations in the Lung Cancer Diagnostics Market consist of blood-based screening approaches, combination multi-omics for precision diagnostics, and portable imaging devices for remote use. Growing numbers of companies are entering into collaborations with research institutions in a strategic manner to co-develop more rapid and scalable diagnostic solutions. There are also efforts toward the greater automation of sample processing and report generation.